{"id":"vonoprazan-amoxicillin-clarithromycin-7-days","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Taste disturbance"},{"rate":"3-8","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the proton pump to reduce gastric acid, creating an optimal environment for antibiotic efficacy. Amoxicillin and clarithromycin are bactericidal and bacteriostatic antibiotics, respectively, that target bacterial cell wall synthesis and protein synthesis. Together, the reduced acid environment and dual antibiotic attack achieve high eradication rates of H. pylori infection.","oneSentence":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:45.893Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in peptic ulcer disease and gastritis"}]},"trialDetails":[{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT06576882","phase":"PHASE3","title":"7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-30","conditions":"Helicobacter Pylori Infection, Gastritis, Vonoprazan","enrollment":326},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT05345210","phase":"PHASE4","title":"Vonoprazan Hp Dual or Triple Eradication Regimes","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-04-25","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT03908619","phase":"PHASE4","title":"A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2019-04-16","conditions":"Helicobacter Pylori Infection","enrollment":252},{"nctId":"NCT03219723","phase":"","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-09-01","conditions":"Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other","enrollment":560}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vonoprazan+amoxicillin+clarithromycin 7 days","genericName":"Vonoprazan+amoxicillin+clarithromycin 7 days","companyName":"Xijing Hospital of Digestive Diseases","companyId":"xijing-hospital-of-digestive-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin). Used for Helicobacter pylori eradication in peptic ulcer disease and gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}